WELCOME
TO OUR HOMEPAGE
InflaRx is a young biotech company developing new therapeutics in the
field of inflammation. InflaRx consists of a team of internationally recognized
researchers and clinicians who have dedicated their careers to translate their
discoveries and expertise into new therapeutic concepts for clinical application.
InflaRx has set its main focus on the SEPSIS indication and has started
the drug development process for new targets within the complement field.
| NEWS | SEPSIS "Hub" Jena | |
- InflaRx successfully closes its 3. financing tranche with the Affentranger Assoc. Group, Private Equity Thüringen GmbH and KFW Mittelstandsbank in December 2008 securing funding for the upcomming years - InflaRx receives large scale R&D fund from the German Federal Minestry of Education and Research (BMBF) in May 2009 |
InflaRx is situated in Jena, Germany as part of the biotech cluster in the Center for Bioinstruments and holds close collaborations with the University Hospital of the Friedrich-Schiller-University in Jena where a worldwide recognized Sepsis HUB has been established. | |
Pictures: Biocentive GmbH